4basebio (LON:4BB) Trading Up 2.3% – Here’s Why

4basebio PLC (LON:4BB) shares were up 2.3% during trading on Wednesday . The stock traded as high as GBX 1,007.50 ($13.52) and last traded at GBX 1,007.50 ($13.52). Approximately 14 shares traded hands during trading, a decline of 99% from the average daily volume of 970 shares. The stock had previously closed at GBX 985 ($13.22).

Analyst Ratings Changes

Separately, Royal Bank Of Canada restated an “outperform” rating and set a GBX 1,600 ($21.47) target price on shares of 4basebio in a research note on Thursday, March 13th.

4basebio Trading Up 2.3%

The firm has a 50-day moving average of GBX 1,105.81 and a two-hundred day moving average of GBX 1,151.14. The firm has a market capitalization of £129.06 million, a P/E ratio of -1,291.67 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB) last announced its quarterly earnings results on Tuesday, May 27th. The company reported GBX (0.94) (($0.01)) earnings per share (EPS) for the quarter. On average, analysts anticipate that 4basebio PLC will post -3.43 EPS for the current year.

Insider Transactions at 4basebio

In other news, insider Heikki Lanckriet purchased 2,400 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were acquired at an average price of GBX 1,205 ($16.17) per share, with a total value of £28,920 ($38,808.37). Corporate insiders own 68.44% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.